By far the best understood clinical application of IFNs biologically is against chronic HCV infections, for which IFN-α has been an approved treatment since 1991, although IFN treatment for HCV was first employed in 1986 with some promise, well before the viral cause of the infection had been identified [19, 20]. Here, IFNA1 is linked to infection.